The Life Sciences team advised MoMa Therapeutics, Inc. on its launch and $86 million Series A financing led by Third Rock Ventures along with additional investors Cormorant Asset Management, Nextech Invest, Creacion Ventures, Casdin Capital, Rock Springs Capital and Alexandria.
MoMa Therapeutics is a biotechnology company that has been created with the goal of establishing a platform focused on the drug discovery of molecular machines by exploiting a key vulnerability inherent to all enzymes in the class: their dependence on well-coordinated, stepwise changes in protein conformation.
Goodwin has advised MoMa Therapeutics since its formation. The team was led by Gabriela Morales-Rivera and Kingsley Taft.
For additional details on the financing, please visit MoMa Therapeutics’ website and read the articles in FierceBiotech and Endpoints.